🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨just out in Lung Cancer Journal MET Alterations in Advanced NSCLC METCrusaders #LCSM lungcancerjournal.info/article/S0169-…

Age-period-cohort effect on lung cancer mortality in Spain, 1982-2021 #LCSM 🇪🇸 lungcancerjournal.info/article/S0169-…

TROP2 expression and SN38 antitumor activity in malignant pleural #mesothelioma cells provide a rationale for antibody-drug conjugate therapy #LCMS #meso lungcancerjournal.info/article/S0169-…

🚨just out in Lung Cancer Journal this important review lead by Martin Reck discussing the role of anti-angiogenic agents for the treatment of resistant NSCLC: rationale, recent updated and perspectives #LCSM 🔗 sciencedirect.com/science/articl…

The European Lung Cancer Congress is ready to start in a few of days *Official hashtag: #ELCC23 👈🏻

🚨🆕 Just out in Lung Cancer Journal this review by Mariana Brandao et al, discussing “Systemic treatment & radiotherapy for pts with NSCLC & #HIV infection” #LCSM Find it here 🔗lungcancerjournal.info/article/S0169-…

🆕Just out in Lung Cancer Journal this interesting editorial by Jarushka Naidoo & . Francesco Cortiula discussing the role of neoadjuvant Osimertinib in resectable NSCLC, harbouring EGFR mutations #LCSM Here the link: lungcancerjournal.info/article/S0169-…

💡#LCSM a new review by Patrick Forde and colleagues, not to be missed!! Neoadjuvant immunotherapy in NSCLC!!! 🚨 lungcancerjournal.info/action/consume…

Happy to see our work on KL-6/MUC1 in pleural meso now out in Lung Cancer Journal: ➤ KL-6 lvls in pleural eff were diagnostic in 2 indep cohorts of pts with pleural meso. ➤⬆️KL-6 lvls and ⬆️MUC1 mRNA expression were associated with⬆️patient outcome. 👉lungcancerjournal.info/article/S0169-…

Current Trial Report on the TARGET trial TARGET is a phase II, open-label, single-arm study of 5-year adjuvant #osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC Primary endpoint: investigator-assessed DFS at 5 years More: bit.ly/46P0VcO

Outcomes with chemo-immunotherapy by #KRAS, STK11, and KEAP1 across PDL1 strata Lung Cancer Journal. KRAS mt enriched in PDL1 high but KRAS with co-mutations in STK11 and KEAP1 enriched in PDL1 negative. Poor OS in KRAS mt with PDL1 0% driven by STK11/KEAP1. lungcancerjournal.info/article/S0169-…

🚨📝 A pragmatic guide for management of adverse events associated with lorlatinib Link here 👉lungcancerjournal.info/article/S0169-… #LCSM ALK Positive

We are pleased to announce that our journal now accepts *Trial in Progress (TiP) papers*, including ongoing phase II and III trials registered with NCI's Clinical Trials Reporting Program. All submission guidelines are available here 🔗sciencedirect.com/journal/lung-c…

Analysis of ctDNA in #HER2 NSCLC receiving pyrotinib and apatinib (PATHER2 study) Lung Cancer Journal. Clearance of ctDNA associated with longer PFS and OS trend. At resistance, chromatin remodeling pathway genes often mutated, on-target resistance uncommon. lungcancerjournal.info/article/S0169-…

Small report on #SCLC subtypes Lung Cancer Journal. Using IHC, differences in subtypes between primary tumors and brain metastases and notable heterogeneity (mixed subtypes) throughout. Matched samples showed changes in subtypes over time. lungcancerjournal.info/article/S0169-…

Report on NGS in squamous NSCLC Lung Cancer Journal from Dr. Joshua Reuss et al. Detected actionable genomic alterations in 22.2% of patients with squamous NSCLC and no history of smoking including #EGFR and #MET. In those with prior smoking, AGAs in 2.4%. lungcancerjournal.info/article/S0169-…

Retrospective review of patients with lung cancer treated at National Cancer Center Hospital in Japan Lung Cancer Journal over the past 20 years shows steady survival gains: 2001-05 mOS 10.7m, 2006-10 OS 14.1m, 2011-15 OS 16.5m, and 2016-21 OS 25.5m. lungcancerjournal.info/article/S0169-…